演題詳細

ポスター / Poster

ポスター 6 (Poster 6) :AML:発症・治療・その他

print

日程
2013年10月11日(金)
時間
16:50 - 17:50
会場
ポスター会場 / Poster (ロイトン札幌 3F ロイトンホールABCD)
座長・司会
安部 明弘 (Akihiro Abe):1
1:藤田保健衛生大学 血液内科
 
前へ戻る

A case of BPDCN developed in MDS as skin and meninges invasion, and then transformed into AML

演題番号 : PS-1-42

山口 晃史 (Terufumi Yamaguchi):1、江口 剛 (Go Eguchi):1、口分田 貴裕 (Takahiro Kumode):1、星田 義彦 (Yoshihiko Hoshida):2、前田 裕弘 (Yasuhiro Maeda):1

1:National Hospital Organization Osaka Minami Medical Center Department of hematology、2:National Hospital Organization Osaka Minami Medical Center Department of hospital pathology

 

The patient was a 70 years old woman and was noted pancytopenia milder than about 2003. Pancytopenia moved her clinical condition from April 2012, and we underwent bone marrow aspiration in June of the year and diagnosed MDS.Multiple bulging eruption appeared to her limbs and trunk from the same period and diagnosed blastic plasmacytoid dendritic cell neoplasm by skin biopsy.Furthermore, we performed lumbar puncture, and meninges invasion of BPDCN was found.The clear abnormal accumulation was found in PET/CT nowhere.After her clinical condition was only skin and meninges invasion at the BPDCN onset, and we followed ALL202-O of JALSG for initial induction therapy, the skin invasion disappeared.She was complicated with Coombs negative hemolytic anemia, but was improved by prednisolone therapy subsequently.We conducted 2 consolidation chemotherapy as additional treatment.However, because she recurred as AML in November of the year, we gave induction therapy, but she finally died for complications.BPDCN is of the progenitor cells of plasmacytoid dendritic cell origin, and it is handled as a special subtype of acute myeloid leukemia by the WHO classification in 2008. It is considered as the curative treatment with allo-SCT, but the disorder is elderly people, and the treatment adaptation does not have it, and the standard chemotherapy is not established, also.We experience a case of BPDCN with the skin and meninges invasion in clinical condition of MDS without bone marrow invasion of BPDCN and finally report our experience with rare clinical condition to develop MDS overt AML.

前へ戻る